Berwyn, Pennsylvania--(Newsfile Corp. - May 10, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, is pleased to announce that its CEO Maria Maccecchini, Ph.D. will ring The Closing Bell at the New York Stock Exchange (NYSE) today, May 10, to celebrate the recent reporting of positive interim data from its ongoing Phase 2a trial in AD and PD.
"We are honored to ring the Closing Bell, and we want to thank our investors for their continued support," said Dr. Maccecchini. "Considering the positive initial interim data we reported in March, we believe Annovis is entering a very exciting period of corporate development. Our two ongoing Phase 2a trials are nearing completion, and we look forward to sharing additional data in the coming months that should set the stage for pivotal trials."
The New York Stock Exchange will stream the Closing Bell ringing on its website: https://www.nyse.com/bell. The bell ringing is scheduled for 4:00 p.m. ET. A video of the bell ringing will also be archived on the same page after livestream.
About Annovis Bio
Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We expect our treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. We have two ongoing Phase 2a studies: one in AD patients and one in both AD and PD patients. For more information on Annovis, please visit the company's website: www.annovisbio.com.
Forward-Looking Statements
Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words, and include, without limitation, statements regarding the timing, effectiveness and anticipated results of ANVS401 clinical trials. Forward-looking statements are based on Annovis Bio, Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including that clinical trials may be delayed. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.
Investor Relations:
Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
Dave@redchip.com
SOURCE: Annovis Bio, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/83476
